Hepatocellular carcinoma (HCC) is one of the most common malignant cancers closely associated with chronic infection by the hepatitis B virus (HBV) or the hepatitis C virus (HCV) throughout the world. In this study, the genetic associations of 20 known polymorphisms in eight candidate genes, including angiotensinogen (AGT), cadherin 1 (CDH1), cyclooxygenase 2 (COX2), monocyte chemotactic protein-1 (MCP1), multidrug resistance 1 (MDR1), chemokine ligand 5 (RANTES), thrombospondin 2 (THBS2), and thrombospondin 4 (THBS4), were analyzed in a large chronic hepatitis B cohort (n = 1,095) recruited from the Korean population. In addition, three polymorphisms in chemokine receptor 4 (CXCR4) and vimentin (VIM) identified in this study were also genotyped. Using logistic regression analysis controlling possible confounding factors, one common (freq.=0.367) promoter polymorphism of MCP1 (MCP1-2518G>A) among analyzed polymorphisms was significantly associated with clearance of HBV infection. The frequency of homozygotes for the MCP1-2518A allele (MCP1-2518A/A) among chronic hepatitis B virus (HBV) carrier patients was significantly higher than that among spontaneously recovered (SR) subjects (17.7% vs. 10.4%)(OR=1.78, P = 0.004). Our findings imply a plausible explanation for the contribution of host genetic determinants to the variable outcome of HBV infection, which might provide valuable information for future genetic study in this area.
Introduction
Chronic infection with hepatitis B virus (HBV) or hepatitis C virus (HCV) has a major role in the development of hepatocellular carcinoma (HCC) (Blumberg, 1984) . Although the virologic features of the two viruses are entirely different, both viruses infect the human liver and initiate a series of processes leading to chronic hepatitis, cirrhosis, and HCC (Watson, 1999) . Some epidemiological findings suggest different modes of disease progression and HCC promotion between HBV and HCV infection (Shiratori et al., 1995; Ikeda et al., 1998; Marotta et al., 2004) . The mechanisms underlying such differences are unknown.
The clinical course of HBV infection varies from spontaneous recovery after acute hepatitis to a chronic persistent infection that may progress to cirrhosis or hepatocellular carcinoma. The mechanisms underlying resolution of acute HBV infection or its progression to chronicity remain undetermined. Age at infection has the most significant impact on the clinical outcome because chronic infection occurs in approximately 90% of infants infected at birth, in 25 to 50% of children infected between the ages of 1 and 5 years, and in less than 5% of those infected during adult life (Stevens et al., 1975; Coursaget et al., 1987; Tassopoulos et al., 1987) . It is well known that the major mode of infection in HBV endemic areas, including Korea, is perinatal transmission (Stevens et al., 1975; Lok et al., 1987) . The mechanisms underlying resolution of acute HBV infection or its progression to chronicity at each age group remain undetermined. When determining the chronicity of HBV infection within a group of patients who are presumed to have been infected at the same age, i.e. perinatally in Korea, it is apparent that the
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outcome of the infection does not appear to be determined by variations in virulence of the viral strains (Thursz et al., 1995; Cacciola et al., 2002) , but that host factors are likely to influence disease outcome (Lin et al., 1989; Chisari and Ferrari 1995) . Thus, it is conceivable that genetic differences play an additional role.
In recent years, a number of studies have shown that various genes could be involved in chronic liver diseases, liver regeneration, autoimmune hepatitis, primary biliary cirrhosis, and alcoholic liver disease, including monocyte chemotactic protein-1 (MCP1) (Marra et al., 1998) , angiotensinogen (AGT) (Ishii et al., 2003; Medina et al., 2003; Moon et al., 2004) , cadherin 1 (CDH1) (Tian et al., 1999; Wei et al., 2002) , cyclooxygenase 2 (COX2) (Shiota et al., 1999) , multidrug resistance 1 (MDR1) (Bao et al., 2000; Ros et al., 2003) , chemokine ligand 5 (RANTES) (Apolinario Fernandez de Sousa and Garcia Monzon, 2003) , thrombospondin 2 (THBS2), thrombospondin 4 (THBS4) (Ishii et al., 2003; Medina et al., 2003; Moon et al., 2004) , chemokine receptor 4 (CXCR4) (Terada et al., 2003; Wald et al., 2004) , and vimentin (VIM) (O'Brien et al., 1989) .
MCP1 is structurally related to the CXC subfamily of cytokines (Copple et al., 2003) . Secretion of MCP1 may contribute to the formation and maintenance of the inflammatory infiltrate observed during chronic liver disease (Marra et al., 1998) . Alcoholic hepatitis and alcoholic cirrhosis are associated with distinct patterns of chemokine expression that are likely to be important factors in determining whether a patient develops acute parenchymal inflammation and alcoholic hepatitis, or chronic septal inflammation and alcoholic cirrhosis (Afford et al., 1998) .
Angiotensinogen (AGT) is expressed in the liver and is cleaved by the enzyme renin in response to lowered blood pressure. AGT is involved in maintaining blood pressure and in the pathogenesis of essential hypertension and preeclampsia (Morgan et al., 1996) . A statistically significant relationship was seen between inheritance of AGT-producing genotypes and the development of progressive hepatic fibrosis (Powell et al., 2000) .
THBS2 and THBS4 belong to the thrombospondin family of disulfide-linked homotrimeric glycoproteins that mediate cell-to-cell and cell-to-matrix interactions. These proteins have been shown to function as potent inhibitors of tumor growth and angiogenesis (Kishi et al., 2003; Wessel et al., 2004) . Previous studies have shown the expression and function of many pro-and antiangiogenic molecules in the setting of nontumoral chronic liver diseases and disease progression (Ishii et al., 2003; Medina et al., 2003; Moon et al., 2004) .
Hepatic RANTES was found to be increased in patients with alcoholic hepatitis (Hirano et al., 2003) . Wald et al. (2004) also showed an important role for the CXCR4 in recruitment and retention of immune cells in the liver during chronic HCV and HBV infection. Similarly, MDR1 and VIM were up-regulated in hepatocytes with severe liver disease (Ros et al., 2003) and in hepatoblastomas where mesenchymal tissue was present in the tumor (O'Brien et al., 1989) .
CDH1 is a calcium-dependent cell-cell adhesion glycoprotein composed of five extracellular cadherin repeats, a transmembrane region and a highly conserved cytoplasmic tail. Mutations in this gene are correlated with gastric, breast, colorectal, thyroid, and ovarian cancers. Loss of function is thought to contribute to progression in cancer by increasing proliferation, invasion, and/or metastasis (Juhasz et al., 2003; Keller and Nigam 2003; Kowalski et al., 2003) .
As a candidate gene association study, we investigated the genetic association of 23 polymorphisms in 10 candidate genes with different outcomes of HBV infection, including clearance of HBV and HCC occurrence.
Materials and Methods

Study population and outcomes
A total of 1,095 Korean subjects having either Table 1 ). The diagnoses of the CC and SR subjects were established by repeated seropositivity for the hepatitis B surface antigen (HBsAg) (Enzygnost ® HBsAg 5.0; Dade Behring, Marburg, Germany) over a 6-month period, and for both anti-HBs (Enzygnost ® Anti-HBs II; Dade Behring, Marburg, Germany) and anti-HBc (AB-Corek; DiaSorin s.r.l., Saluggia, Italy) of the IgG type without HBsAg, respectively. Asymptomatic HBV carriers were also included in CC group. These patients usually have inactive liver disease on liver biopsy. However, it has been known that in these patients, HBV continues to replicate, albeit very low levels, some patients have residual liver disease, and HCC develop frequently. The CC group was further divided into 2 subgroups, i.e., those without (the CH/LC group; n = 339) and those with HCC (the HCC group; n = 327), according to the absence or presence of HCC, respectively. HCC was diagnosed as described previously (Bruix et al., 2001) . We excluded subjects who were positive for anti-HBs but not for anti-HBc, and those positive for anti-HCV or anti-HIV (GENEDIA ® ; Greencross Life Science Corp., Yongin-shi, Korea, HCV ® 3.2; Dong-A Pharmaceutical Co., Seoul, Korea). The patients who had any other types of liver disease such as autoimmune hepatitis, toxic hepatitis, primary biliary cirrhosis, or Budd-Chiari syndrome were also excluded. No patients had a previous history of immunosuppression or anti-viral treatment. Informed consent was obtained from each patient, and the Institutional Review Board of Human Research at Seoul National University Hospital approved the study protocol. The clinical parameters are summarized in Table 1 .
Sequence analysis of the human CXCR4 and VIM
We have sequenced exons and their flanking regions, including the promoter region (1.5 kb), to discover variants in 24 Korean unregulated individual DNA samples using the ABI PRISM 3700 DNA analyzer (Applied Biosystems, Foster City, CA Genotyping with fluorescence polarization detection Twenty polymorphisms of eight candidate genes that might be implicated in clearance of HBV infection and HCC occurrence were genotyped in this study, including -532C＞T, -217G＞A, -6A＞G, and +3889C ＞T in AGT -472insdelA, -285C＞A, +76003A＞C, +84762C＞G, and +86123C＞T in CDH1 (Humar et al., 2002; Nakamura et al., 2002; Wang et al., 2003) ; -162C＞G, +3552G＞A, and +5789T＞C in COX2 (Fritsche et al., 2001) ; -2518G＞A and -2076A＞T in MCP1 (Aguilar et al., 2001; Szalai et al., 2001; Kim et al., 2002) ; +69219G＞T and +91191T＞C in MDR1 (Jamroziak et al., 2004; Kajinami et al., 2004) ; -403G＞A and -28C＞G in RANTES (Liu et al., 1999) ; +36412T＞G in THBS2; and +30275G＞ C in THBS4 (Topol et al., 2001; Boekholdt et al., 2002) . In addition, three polymorphisms in chemokine receptor 4 (CXCR4) and vimentin (VIM), identified in this study, were also genotyped (Table  2) .
For genotyping of 23 polymorphic sites, amplifying primers and probes were designed for TaqMan ® . Primer Express (Applied Biosystems) was used to design both the PCR primers and the MGB TaqMan probes. One allelic probe was labeled with the FAM dye and the other with the fluorescent VIC dye. Typically, PCR was run in the TaqMan Universal Master mix without UNG (Applied Biosystems) at primer concentration of 900 nM and TaqMan MGB-probe concentration of 200 nM. The reaction was performed in a 384-well format in a total reaction volume of 5 µl using 20 ng of genomic DNA. The plate was then placed in a thermal cycler (PE 9700, Applied Biosystems) and heated for 2 min at 50 o C and for 10 min at 95 o C, followed by 40 cycles of 95 o C for 15 s and 60 o C for 1 min. The TaqMan assay plate was then transferred to a Prism 7900HT instrument (Applied Biosystems) where the fluorescence intensity of each well was read. Fluorescence data files from each plate were analyzed by automated software (SDS 2.1). Detailed information concerning the primers can be obtained at the website mentioned above.
Statistics
We examined Lewontin's D' (|D'|) and LD coefficient r 2 between all pairs of biallelic loci (Hedrick, 1987) . Haplotypes of each individual were inferred using the algorithm developed by Stephens et al. (2001) , which (PHASE) uses a Bayesian approach incorporating a priori expectations of haplotypic structure from population genetic and coalescent theory. Genetic effects of inferred haplotypes were analyzed in the same way as SNPs. The permutation test was also performed to test deviation of allelic frequencies of SNPs and haplotypes by using SAS (proc multtest). Distribution was estimated by evaluating the statistics for a random sampling of 10,000 iterated permutations at fixing the total numbers of both the cases and controls. P-value is estimated by the proportion of permutations for which the permutated data test statistic (Ppermuted) is greater than the initially observed test statistic (Pobserved), so permutation P = P (Pobserved ＞ Ppermuted) ( Table 2) . Logistic regression models were used for calculating odds ratios (95% confidential interval) and corresponding P-values controlling for age (continuous value) and sex (male = 0, female = 1) as covariates. In our analysis of HCC occurrence, LC (LC = 1, no LC = 0) and HBeAg (negative = 0, blank = 1, positive = 2) were also used as covariates (Table 3) .
Results
The first critical step in conducting candidate gene studies is the choice of suitable candidate genes that may plausibly play a relevant role in the process or disease under investigation. The candidate gene approach for discovering genetic markers uses experimentally derived a priori knowledge about diseases, and we selected ten candidate genes and their polymorphisms, previously reported the relationship to the various liver diseases, for association study with HBV infection and HCC occurrence.
To discover polymorphisms in CXCR4 and VIM, we performed direct DNA sequencing in 24 unrelated Korean individuals within exons and their boundaries, including the 1.5 kb upstream region of two genes. We identified one sequence variant (+2547C＞T) in exon2 of CXCR4 and five variants (two in promoter [-510A＞G and -312G＞C] , one in 5' UTR [-22G＞C], and two in introns [+6750G＞C and +7379C＞T]) in VIM, respectively (http://www. snp-genetics.com/reference/Supplementary information to HBV.doc). CXCR4+2547C＞T, VIM -510A＞G, and VIM +6750G＞C were selected for larger-scale genotyping (n = 1,095), considering their allele frequencies, haplotype-tagging status, and LDs among polymorphisms. Allele frequencies of all of screened polymorphisms were estimated (http://www.snp-genetics. com/reference/Supplementary information to HBV. doc).
Through pair-wise linkage analysis in a Korean chronic hepatitis B cohort, we have found that three sets of polymorphisms in COX2 and two of MCP1 Logistic regression models were used for calculating odds ratios (95% confidence interval) and corresponding P-values for each SNP site and haplotype using SAS. P-values of co-dominant, dominant, and recessive models are also given. Age (continuous value) and sex (male = 0, female = 1) were adjusted by inclusion in logistic analysis as covariates.
were in complete LD (|D'| = 1 and r 2 ≠ 1), and that four sets of polymorphisms in AGT were in almost complete LD. Another set of polymorphisms in CDH1, RANTES, MDR1, and VIM showed strong LDs within genes (http://www.snp-genetics.com/ reference/Supplementary information to HBV.doc). Among the haplotypes, only ht2 in MCP1, ht1 in AGT, ht1 in CDH1, ht3 in MDR1, and ht2 in RANTES were used for further analysis because other haplotypes were almost (or completely) tagged by a single SNP or the frequencies were too low.
Genotype distributions were analyzed among SR, CC, and HCC subjects using logistic regression models. One common promoter polymorphism in MCP1 (MCP1-2518G＞A) was found to be significantly associated with clearance of HBV infection, whereas no significant associations were observed between other candidate gene polymorphisms and the clearance of HBV infection ( Table 2 ). The frequency of MCP1-2518A allele (MCP1-2518A/A) among the chronic hepatitis B virus (HBV) carrier patients was significantly higher than for the spontaneously recovered (SR) subjects (38.8% vs. 33.4%) (permutation P = 0.01). Similarly, the effect of the homozygote for the "A" allele of -2518G/A also was apparent in the referent model (OR = 1.32, P = 0.009, Table 3 ). Consistent associations revealed in referent-and recessive-analyzing models clearly demonstrated the recessive mode of effect of the "A" allele of -2518G/A. In further haplotype association analysis, ht2 [A-A] showed similar association with clearance of HBV. However, considering that ht2 is mostly (＞ 93%) tagged by 2518G＞A, this genetic effect might be coming from -2518G＞A. In the analysis of HCC occurrence in Korean population, all candidate gene polymorphisms were not associated (Table 2) .
Discussion
MCP1, a member of the small inducible gene (SIG) family, plays a role in the recruitment of monocytes to sites of injury and infection. It has been reported that MCP polymorphisms in the regulatory region affect the level of MCP1 expression in response to an inflammatory stimulus. Interestingly, the associated polymorphism (MCP1-2518G＞A), which showed significant association with clearance of HBV, has been reported to alter MCP1 expression, whereas no effect by the other promoter variant (MCP1-2076A＞T) has been reported (Rovin et al., 1999) . IL1B-treated peripheral blood mononuclear cells from individuals heterozygous or homozygous for the G allele at MCP1-2518G＞A produce more MCP1 than cells from individuals homozygous for the A allele (Rovin et al., 1999; Cho et al., 2004) . Altered level of MCP1 expression due to genotype allele could contribute to the formation and maintenance of the inflammatory infiltrate during chronic liver disease and severe hepatic inflammation and fibrosis (Marra et al., 1998; Muhlbauer et al., 2003) . Involvement of MCP1 polymorphisms in the regulatory region has been reported in various diseases including asthma (Szalai et al., 2001) , systemic lupus erythematosus (Aguilar et al., 2001; Kim et al., 2002) , HCV progression (Muhlbauer et al., 2003; Tagami et al., 2003) , and HBV infection in this study. Different MCP-1 expressions by alternative alleles of -2518G＞A (Rovin et al., 1999; Muhlbauer et al., 2003) consistently suggest functional and/or causal effects of this important variant.
The functional effects of MCP1-2518G＞A on the progression and severity of various diseases were mainly accompanied by the elevated levels of MCP1 due to G allele of MCP1-2518G＞A, whereas A allele of MCP1-2518G＞A, causing lower level of MCP1, contributed to the chronicity of HBV in this study. Although the mechanisms underlying clearance of HBV infection by lower MCP1 expression of the "A" allele of MCP1-2518G＞A are not completely understood, several clues might suggest possible explanations. For instance, MCP-1 might contribute to the formation and maintenance of the inflammatory infiltrate observed during chronic liver disease (Marra et al., 1998) . In an animal study, MCP1-deficient mice were unable to mount type 2 helper cell (TH2) responses (Gu et al., 2000) . Consequently, these mice did not accomplish the immunoglobulin subclass switch that is characteristic of TH2 responses and were resistant to Leishmania major. MCP1 influences both innate immunity, through effects on monocytes, and adaptive immunity, through control of T helper cell polarization (Gu et al., 2000) .
The effects of MCP1 polymorphisms on the resolution of HBV infection were not dramatic in the present study. However, when considering 1) that there were evidences for functional differences mediated by MCP1-2518G＞A (Rovin et al., 1999; Cho et al., 2004) , consequently, affecting disease susceptibility of various diseases in previous studies (Aguilar et al.; Szalai et al., 2001; Kim et al., 2002) , (Rovin et al., 1999; Muhlbauer et al., 2003; Tagami et al., 2003) , and 2) that altered level of MCP1 expression have been reported to be involved in the inflammatory infiltrate during chronic liver disease and severe hepatic inflammation and fibrosis (Marra et al., 1998; Muhlbauer et al., 2003) , the significance of associations with the clearance of HBV infection might be noteworthy. Further biological and/or functional evidence would be needed to confirm the suggestive associations of MCP1 polymorphisms with HBV infection.
In summary, we examined the genetic association of 23 polymorphisms in ten candidate genes. Among 23 polymorphisms, one common promoter variant in MCP1 (-2518G＞A), which is associated with lower MCP1 expression, was significantly associated with the resolution of HBV infection in a Korean HBV study. Haplotype analysis revealed that MCP1-ht2 [A-A] was also significantly associated with HBV clearance, which possibly tracks the genetic effect of the promoter variant. Our findings imply that variations in the genes governing the level of constitutive and inducible MCP1 are an important factor that might explain the variable outcome of HBV infection and offer an approach to elucidating the molecular mechanisms of HBV clearance. This finding might also provide a new perspective on antiviral approaches for the treatment of patients with chronic hepatitis B.
